Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
07
11
2022
received:
08
07
2022
accepted:
11
09
2022
pubmed:
6
10
2022
medline:
26
10
2022
entrez:
5
10
2022
Statut:
ppublish
Résumé
Hepatorenal syndrome (HRS) contributes to significant morbidity and mortality in hospitalised patients with cirrhosis. To examine recent trends, magnitude and outcomes of HRS in the National Inpatient Sample (NIS) database METHODS: Among the NIS database on cirrhosis hospitalisations (2016-2019) due to alcohol (ALD), chronic viral hepatitis (CVH), or NASH and complicated by acute kidney injury (AKI) were analyzed. Of 113,454 hospitalisations, 18,735 (16.5%) had HRS (mean age 56 years, 36% females, 68% whites, 80% ALD, 7% NASH) with a stable trend over time. Among 1:1 propensity-matched 36,090 hospitalisations, the odds of HRS were 12% higher in NASH versus CVH. Based on weighted national estimates, there were 27,180 (8.3 per 100,000 US population) HRS hospitalisations in 2019, with economic burden of $4.2 billion USD. Mean hospitalisation and total charges (ALD vs. CVH vs. NASH) were 11 versus 10.8 versus 9.2 days and 151,000 versus 157,000 versus 120,000 USD, respectively; p < 0.001. In-hospital mortality was 18.9%, higher in HRS (25.8 vs. 12%, p < 0.001), and decreased by 15% annually. Survivors were more likely to be discharged to short- or long-term care facilities (HRS vs. non-HRS [42 vs. 27%, p < 0.001]); only 28.7% received palliative care. HRS was the cause of AKI in 16.5% of patients hospitalised with cirrhosis and conferred significant healthcare burden with 27,180 HRS hospitalisations in 2019 and requiring an estimated 4.2 billion USD for hospital care. While there has been a decrease in in-hospital mortality over time, it remained high at 23.7% in 2019 in those with HRS.
Sections du résumé
BACKGROUND
Hepatorenal syndrome (HRS) contributes to significant morbidity and mortality in hospitalised patients with cirrhosis.
AIMS
To examine recent trends, magnitude and outcomes of HRS in the National Inpatient Sample (NIS) database METHODS: Among the NIS database on cirrhosis hospitalisations (2016-2019) due to alcohol (ALD), chronic viral hepatitis (CVH), or NASH and complicated by acute kidney injury (AKI) were analyzed.
RESULTS
Of 113,454 hospitalisations, 18,735 (16.5%) had HRS (mean age 56 years, 36% females, 68% whites, 80% ALD, 7% NASH) with a stable trend over time. Among 1:1 propensity-matched 36,090 hospitalisations, the odds of HRS were 12% higher in NASH versus CVH. Based on weighted national estimates, there were 27,180 (8.3 per 100,000 US population) HRS hospitalisations in 2019, with economic burden of $4.2 billion USD. Mean hospitalisation and total charges (ALD vs. CVH vs. NASH) were 11 versus 10.8 versus 9.2 days and 151,000 versus 157,000 versus 120,000 USD, respectively; p < 0.001. In-hospital mortality was 18.9%, higher in HRS (25.8 vs. 12%, p < 0.001), and decreased by 15% annually. Survivors were more likely to be discharged to short- or long-term care facilities (HRS vs. non-HRS [42 vs. 27%, p < 0.001]); only 28.7% received palliative care.
CONCLUSION
HRS was the cause of AKI in 16.5% of patients hospitalised with cirrhosis and conferred significant healthcare burden with 27,180 HRS hospitalisations in 2019 and requiring an estimated 4.2 billion USD for hospital care. While there has been a decrease in in-hospital mortality over time, it remained high at 23.7% in 2019 in those with HRS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1486-1496Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, et al. Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: a prospective cohort study. Int J Nephrol. 2015;2015:108139.
Russ KB, Stevens TM, Singal AK. Acute kidney injury in patients with cirrhosis. J Clin Transl Hepatol. 2015;3(3):195-204.
Jamil K, Huang X, Lovelace B, Pham AT, Lodaya K, Wan G. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records. J Med Econ. 2019;22(5):421-9.
Singal AK, Jackson B, Pereira GB, Russ KB, Fitzmorris PS, Kakati D, et al. Biomarkers of renal injury in cirrhosis: association with acute kidney injury and recovery after liver transplantation. Nephron. 2018;138(1):1-12.
Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, et al. Diagnosis, evaluation, and Management of Ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-48.
Gines P, Sola E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers. 2018;4(1):23.
Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105(1):229-36.
Arroyo V, Moreau R, Jalan R. Acute-on-chronic liver failure. N Engl J Med. 2020;382(22):2137-45.
Huelin P, Solà E, Elia C, Solé C, Risso A, Moreira R, et al. Neutrophil gelatinase-associated lipocalin for assessment of acute kidney injury in cirrhosis: a prospective study. Hepatology. 2019;70(1):319-33.
Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document. J Hepatol. 2019;71(4):811-22.
Nanda A, Reddy R, Safraz H, Salameh H, Singal AK. Pharmacological therapies for hepatorenal syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2018;52(4):360-7.
Boyer TD, Sanyal AJ, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl. 2011;17(11):1328-32.
Singal AK, Hasanin M, Kaif M, Wiesner RW, Kuo YF. MELD stratified outcomes among recipients with diabetes or hypertension: simultaneous liver kidney versus liver alone. J Clin Gastroenterol. 2018;52(1):67-72.
Hmoud B, Kuo YF, Wiesner RH, Singal AK. Outcomes of liver transplantation alone after listing for simultaneous kidney: comparison to simultaneous liver kidney transplantation. Transplantation. 2015;99(4):823-8.
Poonja Z, Brisebois A, van Zanten SV, Tandon P, Meeberg G, Karvellas CJ. Patients with cirrhosis and denied liver transplants rarely receive adequate palliative care or appropriate management. Clin Gastroenterol Hepatol. 2014;12(4):692-8.
Pant C, Jani BS, Desai M, Deshpande A, Pandya P, Taylor R, et al. Hepatorenal syndrome in hospitalized patients with chronic liver disease: results from the Nationwide inpatient sample 2002-2012. J Invest Med. 2016;64(1):33-8.
Dang K, Hirode G, Singal AK, Sundaram V, Wong RJ. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Am J Gastroenterol. 2020;115(1):96-104.
Singal AK, Arsalan A, Dunn W, Arab JP, Wong RJ, Kuo YF, et al. Alcohol-associated liver disease in the United States is associated with severe forms of disease among young, females and Hispanics. Aliment Pharmacol Ther. 2021;54(4):451-61.
Singal AK, Ahmed Z, Axley P, Arora S, Arab JP, Haas A, et al. Hospitalisations for acute on chronic liver failure at academic compared to non-academic centers have higher mortality. Dig Dis Sci. 2020;66:1306-14.
Singal AK, Salameh H, Kamath PS. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment Pharmacol Ther. 2014;40(1):105-12.
Desai AP, Knapp SM, Orman ES, Ghabril MS, Nephew LD, Anderson M, et al. Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis - a US population-based study. J Hepatol. 2020;73(5):1092-9.
Desai AP, Mohan P, Nokes B, Sheth D, Knapp S, Boustani M, et al. Increasing economic burden in hospitalized patients with cirrhosis: analysis of a National Database. Clin Transl Gastroenterol. 2019;10(7):e00062.
Tariq R, Singal AK. Management of hepatorenal syndrome: a review. J Clin Transl Hepatol. 2020;8(2):192-9.
Singal AK, Hasanin M, Kaif M, Wiesner R, Kuo YF. Nonalcoholic steatohepatitis is the Most rapidly growing indication for simultaneous liver kidney transplantation in the United States. Transplantation. 2016;100(3):607-12.
Formica RN, Aeder M, Boyle G, Kucheryavaya A, Stewart D, Hirose R, et al. Simultaneous liver-kidney allocation policy: a proposal to optimize appropriate utilization of scarce resources. Am J Transplant. 2016;16(3):758-66.
Wilk AR, Booker SE, Stewart DE, Wiseman A, Gauntt K, Mulligan D, et al. Developing simultaneous liver-kidney transplant medical eligibility criteria while providing a safety net: a 2-year review of the OPTN's allocation policy. Am J Transplant. 2021;21(11):3593-607.
Samoylova ML, Wegermann K, Shaw BI, Kesseli SJ, Au S, Park C, et al. The impact of the 2017 kidney allocation policy change on simultaneous liver-kidney utilization and outcomes. Liver Transpl. 2021;27(8):1106-15.
Rush B, Walley KR, Celi LA, Rajoriya N, Brahmania M. Palliative care access for hospitalized patients with end-stage liver disease across the United States. Hepatology. 2017;66(5):1585-91.
Adejumo AC, Kim D, Iqbal U, Yoo ER, Boursiquot BC, Cholankeril G, et al. Suboptimal use of inpatient palliative care consultation may lead to higher readmissions and costs in end-stage liver disease. J Palliat Med. 2020;23(1):97-106.
Quinn KL, Shurrab M, Gitau K, Kavalieratos D, Isenberg SR, Stall NM, et al. Association of receipt of palliative care interventions with health care use, quality of life, and symptom burden among adults with chronic noncancer illness: a systematic review and meta-analysis. JAMA. 2020;324(14):1439-50.
May P, Normand C, Cassel JB, del Fabbro E, Fine RL, Menz R, et al. Economics of palliative care for hospitalized adults with serious illness: a meta-analysis. JAMA Intern Med. 2018;178(6):820-9.
Beck KR, Pantilat SZ, O'Riordan DL, Peters MG. Use of palliative care consultation for patients with end-stage liver disease: survey of liver transplant service providers. J Palliat Med. 2016;19(8):836-41.
Esteban JPG, Rein L, Szabo A, Saeian K, Rhodes M, Marks S. Attitudes of liver and palliative care clinicians toward specialist palliative care consultation for patients with end-stage liver disease. J Palliat Med. 2019;22(7):804-13.
Vijeratnam SS, Candy B, Craig R, Marshall A, Stone P, Low JTS. Palliative care for patients with end-stage liver disease on the liver transplant waiting list: an international systematic review. Dig Dis Sci. 2021;66:4072-89.
Kaewput W, Thongprayoon C, Dumancas CY, Kanduri SR, Kovvuru K, Kaewput C, et al. In-hospital mortality of hepatorenal syndrome in the United States: nationwide inpatient sample. World J Gastroenterol. 2021;27(45):7831-43.
Cullaro G, Rubin JB, Fortune BE, Crawford CV, Verna EC, Hsu CY, et al. Association between kidney dysfunction types and mortality among hospitalized patients with cirrhosis. Dig Dis Sci. 2022;67(7):3426-35.
Thongprayoon C, Kaewput W, Petnak T, O'Corragain OA, Boonpheng B, Bathini T, et al. Impact of palliative care services on treatment and resource utilization for hepatorenal syndrome in the United States. Med (Basel). 2021;8(5):21.
Karagozian R, Bhardwaj G, Wakefield DB, Verna EC. Acute kidney injury is associated with higher mortality and healthcare costs in hospitalized patients with cirrhosis. Ann Hepatol. 2019;18(5):730-5.
Nadkarni GN, Simoes PK, Patel A, Patel S, Yacoub R, Konstantinidis I, et al. National trends of acute kidney injury requiring dialysis in decompensated cirrhosis hospitalisations in the United States. Hepatol Int. 2016;10(3):525-31.
Patidar KR, Naved MA, Grama A, Adibuzzaman M, Aziz Ali A, Slaven JE, et al. Acute kidney disease is common and associated with poor outcomes in patients with cirrhosis and acute kidney injury. J Hepatol. 2022;77:108-15.